Skip to main content

Blum Robert I's Form 4 filing

Cytokinetics Inc (CYTK) · filed Sep 15, 2026

Accession no.
0001061983-26-000094
Filed
Sep 15, 2026, 5:20 PM ET
Trade date
Sep 14-15, 2026
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $7.34M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Blum Robert ICIK 0001288859Director, Officer (President & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 14, 2026Common StockMOption exerciseAcquired+7,500$10.60+$79,500385,320Direct
Sep 14, 2026Common StockSSaleDisposed−7,500$73.44−$550,800377,820Direct
Sep 14, 2026Common StockGGiftDisposed−1,350$0.00$0376,470Direct
Sep 14, 2026Common StockGGiftDisposed−97,926$0.00$0278,544Direct
Sep 14, 2026Common StockGGiftAcquired+97,926$0.00$097,926Indirect
Sep 15, 2026Common StockSSaleDisposed−97,926$69.33−$6,789,209.580Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 14, 2026Common StockMOption exerciseDisposed−7,500$0.00$0156,745Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)